Table I-44Placebo-controlled trials of mirtazapine

Domains Pertaining to Strength of EvidenceMagnitude of EffectStrength of Evidence
Number of Studies;
Number of Subjects
Risk of Bias; Design/QualityConsistencyDirectnessPrecisionSummary Effect Size (95% CI)High, Moderate, Low, Insufficient
PTSD Symptom Reduction: DTS
1; 29Medium; RCTNA, single studyDirectImpreciseWMD −9.5, p=nsInsufficient
PTSD Symptom Reduction: SPRINT
1; 29Medium; RCTNA, single studyDirectImpreciseWMD −3.76, p=nsInsufficient
PTSD Symptom Reduction: SIPS
1; 29Medium; RCTNA, single studyDirectImpreciseWMD −10.8, p<0.05Insufficient
Prevention/reduction of comorbid depression: HADS-D
1; 29Medium; RCTNA, single studyDirectImpreciseWMD −1.7, p=nsInsufficient
Prevention/reduction of comorbid anxiety: HADS-A
1; 29Medium; RCTNA, single studyDirectImpreciseWMD −1.6, p<0.05Insufficient

From: Appendix I, Strength of Evidence

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 207.
Forman-Hoffman V, Middleton JC, Feltner C, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.